1.74
price down icon1.69%   -0.03
pre-market  Pre-mercato:  1.73   -0.01   -0.57%
loading
Precedente Chiudi:
$1.77
Aprire:
$1.78
Volume 24 ore:
2.13M
Relative Volume:
0.54
Capitalizzazione di mercato:
$1.20B
Reddito:
$711.41M
Utile/perdita netta:
$-133.73M
Rapporto P/E:
-9.1579
EPS:
-0.19
Flusso di cassa netto:
$-199.99M
1 W Prestazione:
-4.40%
1M Prestazione:
+6.75%
6M Prestazione:
+14.47%
1 anno Prestazione:
+62.62%
Intervallo 1D:
Value
$1.73
$1.80
Intervallo di 1 settimana:
Value
$1.73
$1.8275
Portata 52W:
Value
$1.12
$2.035

Opko Health Inc Stock (OPK) Company Profile

Name
Nome
Opko Health Inc
Name
Telefono
305-575-4181
Name
Indirizzo
4400 BISCAYNE BLVD., MIAMI, FL
Name
Dipendente
3,930
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
OPK's Discussions on Twitter

Confronta OPK con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Diagnostics & Research icon
OPK
Opko Health Inc
1.74 1.20B 711.41M -133.73M -199.99M -0.19
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
511.68 196.14B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
210.11 150.17B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
422.54 34.36B 3.90B 887.87M 798.08M 10.67
Diagnostics & Research icon
A
Agilent Technologies Inc
118.97 33.93B 6.53B 1.26B 1.31B 4.35
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
179.36 31.62B 15.41B 1.37B 2.11B 7.50

Opko Health Inc Stock (OPK) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-06-29 Aggiornamento Barrington Research Mkt Perform → Outperform
2022-12-15 Iniziato H.C. Wainwright Buy
2022-01-24 Downgrade Barrington Research Outperform → Mkt Perform
2021-06-21 Iniziato Ladenburg Thalmann Buy
2019-11-25 Iniziato Piper Jaffray Overweight
2018-03-02 Downgrade JP Morgan Neutral → Underweight
2017-09-14 Downgrade JP Morgan Overweight → Neutral
2016-06-21 Reiterato Standpoint Research Buy
2016-06-03 Iniziato Standpoint Research Buy
2016-03-31 Reiterato Barrington Research Outperform
2015-10-16 Iniziato JP Morgan Overweight
2015-09-11 Downgrade Jefferies Buy → Hold
2015-03-03 Downgrade Oppenheimer Outperform → Perform
2014-05-12 Reiterato Oppenheimer Outperform
2014-03-14 Iniziato Oppenheimer Outperform
2013-11-13 Reiterato Ladenburg Thalmann Buy
2013-05-30 Reiterato Ladenburg Thalmann Buy
2012-10-22 Iniziato Barrington Research Outperform
2011-12-01 Reiterato Ladenburg Thalmann Buy
2011-07-14 Iniziato Ladenburg Thalmann Buy
Mostra tutto

Opko Health Inc Borsa (OPK) Ultime notizie

pulisher
Mar 27, 2025

Charles Schwab Investment Management Inc. Has $5.14 Million Stock Position in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat

Mar 27, 2025
pulisher
Mar 27, 2025

Zacks Research Weighs in on OPKO Health FY2027 Earnings - MarketBeat

Mar 27, 2025
pulisher
Mar 27, 2025

OPKO Health Insider Ups Holding During Year - Simply Wall St

Mar 27, 2025
pulisher
Mar 25, 2025

Quote - OPKO Health, Inc.

Mar 25, 2025
pulisher
Mar 24, 2025

HC Wainwright Reaffirms "Buy" Rating for OPKO Health (NASDAQ:OPK) - MarketBeat

Mar 24, 2025
pulisher
Mar 22, 2025

Best Buy, Las Vegas Sands, Globalstar, Opko Health, Agilent: Stock Moves Unveiled - MSN

Mar 22, 2025
pulisher
Mar 22, 2025

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 200,000 Shares - MarketBeat

Mar 22, 2025
pulisher
Mar 21, 2025

PRESS RELEASE ISSUED FEBRUARY 4, 2000 - OPKO Health, Inc.

Mar 21, 2025
pulisher
Mar 21, 2025

Q2 EPS Estimates for OPKO Health Increased by HC Wainwright - MarketBeat

Mar 21, 2025
pulisher
Mar 20, 2025

Chairman & CEO of OPKO Health Phillip Frost Buys More Stock - Yahoo Finance

Mar 20, 2025
pulisher
Mar 19, 2025

H.C. Wainwright maintains Buy on Opko Health, $3 target By Investing.com - Investing.com Canada

Mar 19, 2025
pulisher
Mar 19, 2025

OPKO Health, Entera Bio Partner on Oral Dual Agonist GLP-1 - Contract Pharma

Mar 19, 2025
pulisher
Mar 19, 2025

Forecasting The Future: 6 Analyst Projections For OPKO Health - Benzinga

Mar 19, 2025
pulisher
Mar 18, 2025

Opko and Entera focus on oral care for obesity and metabolic disorders - Yahoo Finance

Mar 18, 2025
pulisher
Mar 18, 2025

Opko Health, Entera Bio sign agreement for oral GLP-1/glucagon dual agonist peptide - BioWorld Online

Mar 18, 2025
pulisher
Mar 18, 2025

OPKO and Entera Link Up to Advance First Oral GLP-1/Glucagon Drug Into Clinic - BioSpace

Mar 18, 2025
pulisher
Mar 18, 2025

OPKO and Entera Bio partner on oral obesity treatment By Investing.com - Investing.com Australia

Mar 18, 2025
pulisher
Mar 18, 2025

Essential Planning LLC. Makes New $506,000 Investment in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat

Mar 18, 2025
pulisher
Mar 17, 2025

OPKO And Entera Bio Team Up For Game-Changing Obesity Pill - Finimize

Mar 17, 2025
pulisher
Mar 17, 2025

OPKO Health, Entera Bio Collaborate To Develop Oral Dual GLP-1/Glucagon Therapy For Obesity - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Labcorp Is Buying BioReference Health’s Cancer Testing Business for $192 Million - Dealbreaker

Mar 17, 2025
pulisher
Mar 17, 2025

OPKO and Entera partner to develop obesity pill - Reuters

Mar 17, 2025
pulisher
Mar 17, 2025

Opko Health, Entera Bio to Collaborate on Tablet for Obesity, Metabolic and Fibrotic Disorders - MarketWatch

Mar 17, 2025
pulisher
Mar 17, 2025

Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity -March 17, 2025 at 08:38 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

OPKO and Entera Bio partner on oral obesity treatment - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

OPKO Health and Entera Bio Enter into Collaboration - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Join Forces to Challenge Injectable Market - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

OPKO Health (NASDAQ:OPK) Earns Buy Rating from HC Wainwright - MarketBeat

Mar 17, 2025
pulisher
Mar 16, 2025

OPKO Health (NASDAQ:OPK) Given "Outperform" Rating at Barrington Research - MarketBeat

Mar 16, 2025
pulisher
Mar 16, 2025

Labcorp Is Buying BioReference Health’s Cancer Testing Business for $192M - MedCity News

Mar 16, 2025
pulisher
Mar 16, 2025

Labcorp is Set to Acquire Select Assets of BioReference Health of OPK - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

OPKO Health (NASDAQ:OPK) Shares Gap UpStill a Buy? - MarketBeat

Mar 15, 2025
pulisher
Mar 14, 2025

Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More. - Barron's

Mar 14, 2025
pulisher
Mar 14, 2025

Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now? - Insider Monkey

Mar 14, 2025
pulisher
Mar 14, 2025

HC Wainwright Reiterates Buy Rating for OPKO Health (NASDAQ:OPK) - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

OPKO Health (NASDAQ:OPK) Earns Outperform Rating from Barrington Research - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

10 Best Stocks Under $3 to Buy Now - Insider Monkey

Mar 13, 2025
pulisher
Mar 13, 2025

H.C. Wainwright maintains $3 target on Opko Health stock By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

H.C. Wainwright maintains $3 target on Opko Health stock - Investing.com

Mar 13, 2025

Opko Health Inc Azioni (OPK) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Opko Health Inc Azioni (OPK) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
FROST PHILLIP MD ET AL
CEO & Chairman
Feb 28 '25
Buy
1.71
67,434
115,312
213,301,448
FROST PHILLIP MD ET AL
CEO & Chairman
Jan 28 '25
Buy
1.47
47,537
70,060
213,234,014
FROST PHILLIP MD ET AL
CEO & Chairman
Jan 17 '25
Buy
1.47
150,000
220,425
213,186,477
FROST PHILLIP MD ET AL
CEO & Chairman
Jan 15 '25
Buy
1.48
500,000
740,850
213,036,477
FROST PHILLIP MD ET AL
CEO & Chairman
Dec 13 '24
Buy
1.59
125,000
199,375
212,536,477
FROST PHILLIP MD ET AL
CEO & Chairman
Dec 11 '24
Buy
1.56
500,000
781,050
212,411,477
FROST PHILLIP MD ET AL
CEO & Chairman
Nov 29 '24
Buy
1.53
199,072
305,376
211,911,477
FROST PHILLIP MD ET AL
CEO & Chairman
Nov 22 '24
Buy
1.59
100,000
159,000
211,712,405
FROST PHILLIP MD ET AL
CEO & Chairman
Nov 14 '24
Buy
1.62
100,000
161,980
211,612,405
FROST PHILLIP MD ET AL
CEO & Chairman
Nov 08 '24
Buy
1.50
280,183
421,535
211,512,405
diagnostics_research DGX
$166.00
price down icon 0.37%
diagnostics_research LH
$231.67
price down icon 0.72%
$148.30
price down icon 1.03%
diagnostics_research WAT
$370.59
price up icon 0.76%
diagnostics_research MTD
$1,193.33
price up icon 0.19%
diagnostics_research IQV
$179.36
price down icon 0.37%
Capitalizzazione:     |  Volume (24 ore):